Pre-made Naratuximab benchmark antibody ( Whole mAb ADC, anti-CD37 therapeutic antibody, Anti-GP52-40/TSPAN26 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-364
Pre-Made Naratuximab biosimilar, Whole mAb ADC, Anti-CD37 Antibody: Anti-GP52-40/TSPAN26 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Naratuximab emtansine | IMGN529 (K7153A) | Debio 1562 | Drug Description. ... The investigational drug is in clinical trials for the potential treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, B-Cell Lymphomas. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-364-1mg | 1mg | Inquiry | ||
| GMP-Bios-ab-364-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-364-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-364-xmg | >100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Naratuximab biosimilar, Whole mAb ADC, Anti-CD37 Antibody: Anti-GP52-40/TSPAN26 therapeutic antibody |
| INN Name | Naratuximab |
| Target | CD37 |
| Format | Whole mAb ADC |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | ImmunoGen;Chronic lymphocytic leukaemia |
| Conditions Approved | na |
| Conditions Active | Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma |
| Conditions Discontinued | Chronic lymphocytic leukaemia |
| Development Tech | na |

